Acoramidis significantly reduced all-cause mortality in both wild-type and variant amyloid cardiomyopathy through 42 months of the ATTRibute-CM study. The study demonstrated consistent efficacy in ...
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ...
BETHESDA, Md. — The Automotive Aftermarket Industry Association (AAIA) has released what it describes as the first open industry standard for product-specific attributes. Standardization of ...
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio” or the "Company”), a new type of biopharmaceutical company focused on genetic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback